Casimersen

DRUG2 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Duchenne Muscular Dystrophy

Phase 3

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

TerminatedNCT03532542

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2018-08-02End: 2023-07-26Updated: 2024-09-19

Unknown Phase

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Enrolling by invitationNCT06606340

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2019-01-07End: 2033-12-31Target: 300Updated: 2025-09-10

Related Papers

Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.

2026-04-10